Tags |
|
|
Links |
|
|
E-Folder - Supporting Remote Team Performance
Introduction
At CAL we have been involved with remote teams for a number of years and have spend time understanding was makes a good team and what makes a great team. The problems with
At CAL we have been involved with remote teams for a number of years and have spend time understanding was makes a good team and what makes a great team. The problems with
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
a team that is not located in one place are different to standard office-based team issues and although there is no magic wand or standard problems here are a few classic issues.
Comm
Comm
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
unications – It can be frustrating to be waiting on information from other team members and this can cause tension in the team. Of course the cause can be due to poor procedures, lack o
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
f training or inadequate technology, but is a management issue even if it is only a perceived problem. The results of these factors in a remote team will be isolation and the feeling of
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
being out of contact with the organisation’s heart beat.
Collaboration – Where more than one team member is involved in a project or task. This is the fundamental reason why a team ex
Collaboration – Where more than one team member is involved in a project or task. This is the fundamental reason why a team ex
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
ists because of the need to work together. This vital skill set can be anything from non-existent to excellent and is normally the result of a good team, working well and successfully.
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
This comes through team building and working together. If you want to know if your team is a team, ask yourself ‘Are we a team or just a group of individuals working on the same task?’
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
If you find that your team is just a group of individuals, then you need to examine what benefits a team culture would bring.
Control – The management and control of a remote team is
Control – The management and control of a remote team is
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
vital to ensure that issues are identified early and action to correct is taken. By giving control to the team manager or leader, you allow the team to feel both valued and motivated,
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
problems are dealt with and overcome, and productivity increases. Very often an organisation can be working well on one location, meeting all management good practice, but not utilisi
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
g this successful structure throughout the rest of the organisation. Any organisation must have a clear understanding of how effective a team is and learn lessons to replicate successfu
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
l strategies within other teams. It is so often the case that teams become ineffective over a number of years, as early signs of productivity decay are just disregarded or even accepted
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
as the norm.
If a team is working, then the temptation is to ‘leave well alone’, but this inaction can cause problems, for example:
o Motivation – If team members feel there is no fo
If a team is working, then the temptation is to ‘leave well alone’, but this inaction can cause problems, for example:
o Motivation – If team members feel there is no fo
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
cus or commitment to the team you will lose motivation and the teams inner momentum. At best, it will still function - at worst they will be a group of individuals, some of which will
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
be self-motivated, others will not.
o Isolation - This can start as feeling out of contact, but end up as feeling under valued and alone.
o Efficiency – Task will take longer and no
o Isolation - This can start as feeling out of contact, but end up as feeling under valued and alone.
o Efficiency – Task will take longer and no
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
effort will be forthcoming on improving the team working.
o Hostility – Individuals will feel others are letting down the team, or they work harder than another member or team. This is
o Hostility – Individuals will feel others are letting down the team, or they work harder than another member or team. This is
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
usually a result of other factors, but sometimes is the first to surface outside of the team.
o Cost - The team are not working effectively and see no reason to change or worst, see n
o Cost - The team are not working effectively and see no reason to change or worst, see n
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
o one listening to them. The result is a team costing more than they should.
o Competitors – The ultimate price will be losing sales to competitors, which will only add to the frustrat
o Competitors – The ultimate price will be losing sales to competitors, which will only add to the frustrat
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
ions of a team.
o Losing good staff – The key members of the team will not want to stick around and see no commitment to them, so give no commitment to the company.
It is very unlikel
o Losing good staff – The key members of the team will not want to stick around and see no commitment to them, so give no commitment to the company.
It is very unlikel
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
y that you will see every one of these dangers, or that they will have escalated to an unacceptable level. But if you can see any of these issues within your teams, then take action now
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.e-folder.org.ua/article/45613/e-folder-Supporting-Remote-Team-Performance.html">Supporting Remote Team Performance</a>
BB link (for phorums):
[url=http://www.e-folder.org.ua/article/45613/e-folder-Supporting-Remote-Team-Performance.html]Supporting Remote Team Performance[/url]
Related Articles:
What is the Importance of a Press Release?
10 Things to Consider When Starting a New Business
Bookmark it:
|